Page last updated: 2024-11-02

pantoprazole and Hepatocellular Carcinoma

pantoprazole has been researched along with Hepatocellular Carcinoma in 2 studies

Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Kataria, A1
Stolow, E1
Hubbard, H1
Matboli, M1
ElGwad, AA1
Hasanin, AH1
El-Tawdi, A1
Habib, EK1
Elmansy, RA1
Ibrahim, D1
Shehata, H1
Tash, F1

Other Studies

2 other studies available for pantoprazole and Hepatocellular Carcinoma

ArticleYear
Pantoprazole-induced acute hepatocellular and cholestatic hepatitis.
    Postgraduate medical journal, 2022, Volume: 98, Issue:1155

    Topics: Carcinoma, Hepatocellular; Hepatitis; Humans; Liver Neoplasms; Pantoprazole

2022
Pantoprazole attenuates tumorigenesis via inhibition of exosomal secretion in a rat model of hepatic precancerous lesion induced by diethylnitrosamine and 2-acetamidofluorene.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:9

    Topics: 2-Acetylaminofluorene; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Diethyln

2019